CONMED Corporation Adds Mark Kaye to its Board of Directors
CONMED (NYSE: CNMD) announced that Mark Kaye will join its Board of Directors effective February 24th, 2025. Kaye brings extensive experience in finance, accounting, risk management, strategic planning, and operational efficiencies, along with expertise in corporate governance and healthcare.
Kaye currently serves as Executive Vice President and Chief Financial Officer of Elevance Health since 2023. His previous roles include EVP and CFO at Moody's (2021-2023), SVP-CFO at Moody's (2018-2021), and leadership positions at MassMutual and Voya Financial. He has served as a Director on the Board of BCS Financial since 2024.
Both Martha Goldberg Aronson, Chair of CONMED's Board, and Patrick Beyer, President and CEO, expressed enthusiasm about Kaye's addition, highlighting how his healthcare and financial expertise will help guide CONMED's growth opportunities to benefit customers, shareholders, and employees.
CONMED (NYSE: CNMD) ha annunciato che Mark Kaye entrerà a far parte del suo Consiglio di Amministrazione a partire dal 24 febbraio 2025. Kaye porta con sé una vasta esperienza in finanza, contabilità, gestione del rischio, pianificazione strategica e efficienza operativa, insieme a competenze nella governance aziendale e nella sanità.
Kaye attualmente ricopre il ruolo di Vicepresidente Esecutivo e Direttore Finanziario di Elevance Health dal 2023. Le sue esperienze precedenti includono EVP e CFO presso Moody's (2021-2023), SVP-CFO presso Moody's (2018-2021) e posizioni di leadership in MassMutual e Voya Financial. È stato Direttore del Consiglio di BCS Financial dal 2024.
Sia Martha Goldberg Aronson, Presidente del Consiglio di CONMED, che Patrick Beyer, Presidente e CEO, hanno espresso entusiasmo per l'aggiunta di Kaye, sottolineando come la sua esperienza nel settore sanitario e finanziario contribuirà a guidare le opportunità di crescita di CONMED a beneficio di clienti, azionisti e dipendenti.
CONMED (NYSE: CNMD) anunció que Mark Kaye se unirá a su Junta Directiva a partir del 24 de febrero de 2025. Kaye aporta una amplia experiencia en finanzas, contabilidad, gestión de riesgos, planificación estratégica y eficiencias operativas, junto con experiencia en gobernanza corporativa y atención médica.
Kaye actualmente se desempeña como Vicepresidente Ejecutivo y Director Financiero de Elevance Health desde 2023. Sus roles anteriores incluyen EVP y CFO en Moody's (2021-2023), SVP-CFO en Moody's (2018-2021) y posiciones de liderazgo en MassMutual y Voya Financial. Ha sido Director en la Junta de BCS Financial desde 2024.
Tanto Martha Goldberg Aronson, Presidenta de la Junta de CONMED, como Patrick Beyer, Presidente y CEO, expresaron entusiasmo por la incorporación de Kaye, destacando cómo su experiencia en atención médica y finanzas ayudará a guiar las oportunidades de crecimiento de CONMED en beneficio de clientes, accionistas y empleados.
CONMED (NYSE: CNMD)는 Mark Kaye가 2025년 2월 24일부터 이사회의 일원이 될 것이라고 발표했습니다. Kaye는 재무, 회계, 위험 관리, 전략적 계획 및 운영 효율성 분야에서 풍부한 경험을 가지고 있으며, 기업 거버넌스 및 의료 분야에 대한 전문성을 보유하고 있습니다.
Kaye는 현재 2023년부터 Elevance Health의 부사장 겸 최고 재무 책임자로 재직 중입니다. 그의 이전 경력에는 Moody's의 EVP 및 CFO(2021-2023), Moody's의 SVP-CFO(2018-2021) 및 MassMutual과 Voya Financial의 리더십 직책이 포함됩니다. 그는 2024년부터 BCS Financial 이사회에서 이사로 활동하고 있습니다.
CONMED 이사회의 의장인 Martha Goldberg Aronson과 CEO인 Patrick Beyer는 Kaye의 합류에 대한 기대감을 표명하며, 그의 의료 및 재무 전문성이 CONMED의 성장 기회를 안내하여 고객, 주주 및 직원에게 이익이 될 것이라고 강조했습니다.
CONMED (NYSE: CNMD) a annoncé que Mark Kaye rejoindra son Conseil d'Administration à compter du 24 février 2025. Kaye apporte une vaste expérience en finance, comptabilité, gestion des risques, planification stratégique et efficacité opérationnelle, ainsi qu'une expertise en gouvernance d'entreprise et en soins de santé.
Kaye occupe actuellement le poste de Vice-Président Exécutif et Directeur Financier de Elevance Health depuis 2023. Ses précédents postes incluent EVP et CFO chez Moody's (2021-2023), SVP-CFO chez Moody's (2018-2021) et des postes de direction chez MassMutual et Voya Financial. Il est membre du Conseil d'Administration de BCS Financial depuis 2024.
Tant Martha Goldberg Aronson, Présidente du Conseil de CONMED, que Patrick Beyer, Président et CEO, ont exprimé leur enthousiasme quant à l'ajout de Kaye, soulignant comment son expertise en santé et en finance aidera à guider les opportunités de croissance de CONMED au bénéfice des clients, actionnaires et employés.
CONMED (NYSE: CNMD) gab bekannt, dass Mark Kaye ab dem 24. Februar 2025 dem Vorstand beitreten wird. Kaye bringt umfangreiche Erfahrungen in den Bereichen Finanzen, Buchhaltung, Risikomanagement, strategische Planung und operative Effizienz mit, sowie Fachkenntnisse in Unternehmensführung und Gesundheitswesen.
Kaye ist seit 2023 als Executive Vice President und Chief Financial Officer von Elevance Health tätig. Zu seinen früheren Positionen gehören EVP und CFO bei Moody's (2021-2023), SVP-CFO bei Moody's (2018-2021) sowie Führungspositionen bei MassMutual und Voya Financial. Seit 2024 ist er außerdem Direktor im Vorstand von BCS Financial.
Sowohl Martha Goldberg Aronson, Vorsitzende des CONMED-Vorstands, als auch Patrick Beyer, Präsident und CEO, äußerten sich begeistert über Kaye's Hinzukommen und hoben hervor, wie seine Expertise im Gesundheitswesen und in Finanzen dazu beitragen wird, die Wachstumschancen von CONMED zum Nutzen der Kunden, Aktionäre und Mitarbeiter zu lenken.
- Addition of experienced financial executive to Board of Directors
- New director brings healthcare industry expertise
- New director has strong background in finance, accounting, and risk management
- Strategic addition may help guide company's growth opportunities
- None.
“My fellow directors and I are extremely pleased to welcome Mark to the board,” said Martha Goldberg Aronson, Chair of CONMED’s Board of Directors. “Mark brings a wealth of experience to CONMED, including deep knowledge across finance, accounting, risk management, strategic planning, and operational efficiencies. He also brings a strong background and expertise in both corporate governance and healthcare. Mark’s skills and insights will help guide CONMED’s future direction.”
“Mark is an outstanding addition to our board,” said Patrick Beyer, President and Chief Executive Officer of CONMED. “We are excited to benefit from his valuable healthcare and financial expertise as we continue to execute on our many growth opportunities, which will benefit our customers, shareholders, and employees.”
Mr. Kaye has served as the Executive Vice President and Chief Financial Officer of Elevance Health (Elevance) since 2023. Prior to joining Elevance, he served as the Executive Vice President and Chief Financial Officer of Moody’s Corporation (Moody’s) from 2021 to 2023, with responsibility for all global finance activities across the company and as Senior Vice President-Chief Financial Officer from 2018 to 2021. Prior to Moody’s, he served as Senior Vice President and Head of Financial Planning and Analysis at Massachusetts Mutual Life Insurance Company (MassMutual) from 2016 until 2018, and Chief Financial Officer of MassMutual
Prior to MassMutual, Mr. Kaye served as Chief Financial Officer and Senior Vice President, Retirement Solutions, at Voya Financial (formerly ING
About CONMED Corporation
CONMED is a medical technology company that provides devices and equipment for surgical procedures. The Company’s products are used by surgeons and other healthcare professionals in a variety of specialties including orthopedics, general surgery, gynecology, thoracic surgery, and gastroenterology. For more information, visit www.conmed.com.
Forward-Looking Statements
This press release may contain forward-looking statements based on certain assumptions and contingencies that involve risks and uncertainties, which could cause actual results, performance, or trends to differ materially from those expressed in the forward-looking statements herein or in previous disclosures. For example, in addition to general industry and economic conditions, factors that could cause actual results to differ materially from those in the forward-looking statements may include, but are not limited to the risk factors discussed in the Company's Annual Report on Form 10-K for the full year ended December 31, 2024 and other risks and uncertainties, which may be detailed from time to time in reports filed by CONMED with the SEC. Any and all forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and relate to the Company’s performance on a going-forward basis. The Company believes that all forward-looking statements made by it have a reasonable basis, but there can be no assurance that management’s expectations, beliefs or projections as expressed in the forward-looking statements will actually occur or prove to be correct.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250225651622/en/
CONMED Corporation
Todd W. Garner
Chief Financial Officer
727-214-2975
ToddGarner@conmed.com
Source: CONMED Corporation
FAQ
When will Mark Kaye join CONMED's (CNMD) Board of Directors?
What experience does Mark Kaye bring to CONMED (CNMD)?
What is Mark Kaye's current position before joining CNMD's board?
How might Mark Kaye's appointment impact CNMD's business strategy?
What previous financial leadership roles has Mark Kaye held before joining CNMD's board?
